Processa Pharmaceuticals, Inc.: total liabilities
Total liabilities for Processa Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Processa Pharmaceuticals, Inc. financial histories
What this measure means
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
Exact concept: us-gaap:Liabilities. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2012-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 2,236,253 | USD | 2026-03-18 | 10-K · 0001493152-26-011204 |
| At date | 2024-12-31 | 1,533,118 | USD | 2026-03-18 | 10-K · 0001493152-26-011204 |
| At date | 2023-12-31 | 797,484 | USD | 2025-03-20 | 10-K · 0001641172-25-000070 |
| At date | 2022-12-31 | 1,149,110 | USD | 2024-03-29 | 10-K · 0001493152-24-011976 |
| At date | 2021-12-31 | 978,405 | USD | 2023-03-30 | 10-K · 0001493152-23-009730 |
| At date | 2020-12-31 | 2,274,911 | USD | 2022-03-30 | 10-K · 0001493152-22-008156 |
| At date | 2019-12-31 | 2,870,584 | USD | 2021-03-25 | 10-K · 0001493152-21-006807 |
| At date | 2018-12-31 | 2,780,050 | USD | 2020-03-06 | 10-K · 0001493152-20-003534 |
| At date | 2017-12-31 | 2,609,776 | USD | 2019-04-08 | 10-K/A · 0001493152-19-004990 |
| At date | 2016-12-31 | 97,692 | USD | 2018-04-16 | 10-K · 0001493152-18-005248 |
| At date | 2015-12-31 | 2,083,128 | USD | 2017-09-25 | 10-K · 0001393905-17-000290 |
| At date | 2014-12-31 | 1,337,929 | USD | 2017-06-19 | 10-K · 0001393905-17-000190 |
| At date | 2013-12-31 | 1,267,175 | USD | 2015-04-14 | 10-K · 0001393905-15-000193 |
| At date | 2012-12-31 | 1,321,810 | USD | 2014-03-27 | 10-K · 0001393905-14-000131 |
Related financial histories
- Processa Pharmaceuticals, Inc.: total assets
- Processa Pharmaceuticals, Inc.: stockholders equity
- Processa Pharmaceuticals, Inc.: cash and cash equivalents
- Processa Pharmaceuticals, Inc.: net income or loss
- Processa Pharmaceuticals, Inc.: operating cash flow
- Processa Pharmaceuticals, Inc.: capital expenditure payments
- Processa Pharmaceuticals, Inc.: revenue
- Processa Pharmaceuticals, Inc.: financing cash flow
- Processa Pharmaceuticals, Inc.: investing cash flow
- Processa Pharmaceuticals, Inc.: retained earnings or deficit
- Processa Pharmaceuticals, Inc.: basic weighted-average shares
- Processa Pharmaceuticals, Inc.: diluted weighted-average shares
- Processa Pharmaceuticals, Inc.: basic earnings per share
- Processa Pharmaceuticals, Inc.: diluted earnings per share
- Processa Pharmaceuticals, Inc.: income tax expense or benefit
- Processa Pharmaceuticals, Inc.: net property, plant and equipment
- Processa Pharmaceuticals, Inc.: share-based compensation expense
- Processa Pharmaceuticals, Inc.: operating income or loss
- Processa Pharmaceuticals, Inc.: current assets
- Processa Pharmaceuticals, Inc.: interest expense
- Processa Pharmaceuticals, Inc.: current liabilities
- Processa Pharmaceuticals, Inc.: current accounts payable
- Processa Pharmaceuticals, Inc.: net finite-lived intangible assets
- Processa Pharmaceuticals, Inc.: operating expenses
- Processa Pharmaceuticals, Inc.: net inventory
- Processa Pharmaceuticals, Inc.: gross profit
- Processa Pharmaceuticals, Inc.: selling, general and administrative expense
- Processa Pharmaceuticals, Inc.: research and development expense
Inspect the source
- Entity
- Processa Pharmaceuticals, Inc. / CIK 0001533743
- Captured
- 2026-09-20T09:16:31.348Z
- SEC response SHA-256
5f3216d9024f2a7fc94b315f5bf243c7efb048273a6be394a2f74186d7af2a31
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001533743.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))